title: Serum p53 antibody detection in patients with impaired lung function.
abstract: BACKGROUND
  TP53 gene mutations can lead to the expression of a dysfunctional protein that in turn may enable genetically unstable cells to survive and change into malignant cells. Mutant p53 accumulates early in cells and can precociously induce circulating anti-p53 antibodies (p53Abs); in fact, p53 overexpression has been observed in pre-neoplastic lesions, such as bronchial dysplasia, and p53Abs have been found in patients with chronic obstructive pulmonary disease, before the diagnosis of lung and other tobacco-related tumors.
  
  
  METHODS
  A large prospective study was carried out, enrolling non-smokers, ex-smokers and smokers with or without the impairment of lung function, to analyze the incidence of serum p53Abs and the correlation with clinicopathologic features, in particular smoking habits and impairment of lung function, in order to investigate their possible role as early markers of the onset of lung cancer or other cancers. The p53Ab levels were evaluated by a specific ELISA in 675 subjects.
  
  
  RESULTS
  Data showed that significant levels of serum p53Abs were present in 35 subjects (5.2%); no difference was observed in the presence of p53Abs with regard to age and gender, while p53Abs correlated with the number of cigarettes smoked per day and packs-year. Furthermore, serum p53Abs were associated with the worst lung function impairment. The median p53Ab level in positive subjects was 3.5 units/ml (range 1.2 to 65.3 units/ml). Only fifteen positive subjects participated in the follow-up, again resulting positive for serum p53Abs, and no evidence of cancer was found in these patients.
  
  
  CONCLUSIONS
  The presence of serum p53Abs was found to be associated with smoking level and lung function impairment, both risk factors of cancer development. However, in our study we have not observed the occurrence of lung cancer or other cancers in the follow-up of positive subjects, therefore we cannot directly correlate the presence of serum p53Abs with cancer risk.
authors: Experimental Research Centre, Regina Elena National Cancer Institute, via delle Messi d'Oro 156, 00158, Rome, Italy. mattioni@ifo.it
authors: Manlio
authors: M
authors: Mattioni
authors: Patrizia
authors: P
authors: Chinzari
authors: Silvia
authors: S
authors: Soddu
authors: Lidia
authors: L
authors: Strigari
authors: Vincenzo
authors: V
authors: Cilenti
authors: Eliuccia
authors: E
authors: Mastropasqua
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D016009:Chi-Square Distribution; D055088:Early Detection of Cancer; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008168:Lung / Q000503:physiopathology*; D008175:Lung Neoplasms / Q000097:blood / Q000209:etiology / Q000276:immunology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000209:etiology / Q000276:immunology* / Q000503:physiopathology; D012129:Respiratory Function Tests; D012307:Risk Factors; D012720:Severity of Illness Index; D012907:Smoking / Q000009:adverse effects; D016540:Smoking Cessation; D000074606:Smoking Prevention; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D001323:Autoantibodies; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
references: Breast Cancer Res Treat. 2005 Sep;93(2):111-5
references: 16187230
references: Environ Mol Mutagen. 2002;39(2-3):216-27
references: 11921192
references: PLoS One. 2012;7(6):e38629
references: 22701684
references: Cancer Res. 2000 Apr 1;60(7):1777-88
references: 10766157
references: Thorax. 2007 Jan;62(1):51-6
references: 16928722
references: Clin Cancer Res. 1996 Oct;2(10):1767-75
references: 9816128
references: Thorax. 2005 Jul;60(7):570-5
references: 15994265
references: Can J Urol. 2003 Aug;10(4):1924-33
references: 14503938
references: Proc Am Thorac Soc. 2008 Dec 1;5(8):811-5
references: 19017734
references: Arch Pathol Lab Med. 2011 Dec;135(12):1570-5
references: 22129186
references: Nat Clin Pract Oncol. 2005 Feb;2(2):90-7; quiz 1 p following 113
references: 16264881
references: Inflamm Bowel Dis. 2007 Jul;13(7):865-73
references: 17285596
references: Lung Cancer. 2003 Jan;39(1):1-13
references: 12499088
references: Oncogene. 2002 Oct 21;21(48):7298-306
references: 12379874
references: J Allergy Clin Immunol. 2005 Sep;116(3):477-86; quiz 487
references: 16159612
references: Oncol Rep. 2002 Mar-Apr;9(2):223-9
references: 11836584
references: Thorax. 2004 Aug;59(8):679-81
references: 15282388
references: Gastroenterology. 1998 Jul;115(1):19-27
references: 9649454
references: Clin Cancer Res. 1998 Feb;4(2):271-5
references: 9516910
references: J Occup Med. 1994 Dec;36(12):1324-8
references: 7884573
references: Nat Med. 1995 Jul;1(7):701-2
references: 7585154
references: Cancer. 2007 Dec 1;110(11):2502-6
references: 17932907
references: Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15
references: 18402527
references: Chem Res Toxicol. 2008 Jan;21(1):160-71
references: 18052103
references: J Natl Cancer Inst. 2005 Feb 16;97(4):251-3
references: 15713956
references: FASEB J. 2005 Jun;19(8):1030-2
references: 15811878
references: Biomarkers. 1999;4(5):381-90
references: 23902358
references: Environ Health Perspect. 1996 May;104 Suppl 3:553-6
references: 8781382
references: Inflamm Bowel Dis. 2004 Sep;10(5):606-11
references: 15472522
references: J Thorac Oncol. 2008 Aug;3(8):819-31
references: 18670299
references: J Biol Chem. 1999 Apr 16;274(16):10911-5
references: 10196169
references: Int J Cancer. 2005 Mar 10;114(1):157-60
references: 15523685
references: Chest. 2006 May;129(5):1305-12
references: 16685023